Compare Adaptive Biotechnologies Corp (ADPT) vs CubeSmart (CUBE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs CubeSmart — how do they compare? Adaptive Biotechnologies Corp trades at $19.95 (market cap $3.33B), while CubeSmart trades at $40.11 (market cap $9.26B). The key difference: CubeSmart is far larger — about 2.8× Adaptive Biotechnologies Corp's market cap, and CubeSmart pays a 5.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | CUBE | |
|---|---|---|
Market Cap | $3.33B | $9.26B |
Sector | Health | Real Estate |
52-Week High | $22.37 | $42.60 |
52-Week Low | $10.24 | $35.36 |
Enterprise Value | $3.19B | $12.75B |
Dividend Yield | — | 5.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CubeSmart (CUBE) trades at $40.88, down 0.24% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.63, beating expectations, and maintains strong profitability with a 28.93% net income margin. Recent news highlights the upcoming Q2 2026 earnings release on July 30, 2026, and a declared dividend of $0.53 per share.
Outlook is balanced with a consensus price target of $43.17 suggesting modest upside, but risks include a high debt load and interest rate sensitivity. The stock offers a solid dividend yield, yet faces headwinds from macroeconomic uncertainty and competitive pressures in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
